Зu1040 АКu1051 ЛЮu1063 ЧЕu1053 НИu1045 Е
Применение ривастигмина у пациентов БА с пове-
денческими и психотическими расстройствами на
стадии умеренно выраженной деменции улучшает не
только когнитивное функционирование больных, но
и положительно влияет на редукцию у них психоти-
ческих и поведенческих расстройств.
Включение ривастигмина в комплексную терапию
этой категории особенно трудных для ухода и лече-
ния пациентов с БА приводит к существенному сни-
жению доз необходимых психотропных препаратов,
а у ряда больных –и к полной отмене всех антипси-
хотических средств, применяемых для купирования
поведенческих и психотических расстройств.
Чрезвычайно важно подчеркнуть, что применение
терапии ривастигмином у пациентов с умеренно вы-
раженной БА и поведенческими расстройствами при-
водит к существенному (до 30 %) снижению време-
ни, затрачиваемому на уход и присмотр за такими па-
циентами, уменьшению уровня стрессовой нагрузки
и улучшению здоровья лиц, ухаживающих за больны-
ми, что сказывается на повышении качества жизни
как самого больного, так и его семьи.
Лu1080 итu1077 ерu1072 атu1091 урu1072 а
1. Гu1072 авu1088 риu1083 лоu1074 ваСИ, Кu1072 алu1099 ынЯБ Сu1086 оцu1080 иаu1083 льu1085 носu1088 реu1076 доu1074 выu1077 е фu1072 акu1090 тоu1088 рыисu1086 осu1090 тоu1103 янu1080 иеpar пu1089 сиu1093 хиu1095 чеu1089 скu1086 огu1086 о зu1076 доu1088 роu1074 вьu1103 я пu1086 ожu1080 илu1086 огu1086 о нu1072 асu1077 елu1077 енu1080 ия// Вu1077 есu1090 тнu1080 икРu1086 ос Аu1052 МН 2002.
|
|
|
№. С 15–0.
2. Alzheimer’ Association. 2008 Alzheimer’ Disease Facts and Figures //
Alzheimer's & Dementia. 2008. Vol. 4. Issue 2. Р 110–33.
3. Croog S.H., Burleson J.A., Sudilovsky A., Baume R.M. Spouse caregivcrs of
Alzheimer patients: problem responses to caregivcr burden // Aging Ment
Health. 2006. Vol. 10. P. 87–00.
4. Cummings J.L., Mega M., Gray K. et al. The Neuropsychiatric Inventory:
comprehensive assessment of psychopathology in dementia // Neurology.
1994. Vol. 44. №12. P. 2308–314.
5. Folstein M.F., Folstein S.E., McHugh P.R. Mini-Mental State. A practical
method of grading the cognitive state of patients for the clinician // Journal
of Psychiatry Research. 1975. Vol. 12. P. 189–98.
6. Gelinas I., Gauthier L., McIntyre M. Development of a functional measure for
persons with Alzheimer's disease: the Disability Assessment for Dementia //
American Journal of Occupational Therapy. 1999. Vol. 53. P. 471–81.
7. Gwyther L., George L. Caregivers for dementia patients: Complex determinants
of well-being and burden // Gerontologist. 1986. Vol. 26(3). P. 245–47.
8. Kochhann R., Borba E., Cerveira M.O., Onyszko D., De Jesus A., Forster L., et
al. Neuropsychiatric symptoms as the main determinant of caregiver burden
in Alzheimer’ disease // Dement .Neuropsychol. 2011. Vol. 5(3). P. 203–08.
9. Mahoney R., Regan C., Katona C. Anxiety and depression in family caregivers
of people with Alzheimer disease: the LASER-AD study // Am J Geriatr
Psychiatrv. 2005. Vol. 13. P. 795–01.
10. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer`s
disease: report of the NINCDS-ADRDA Work Group under the auspices of
Department of Health and Human Services Task Force on Alzheimer`s disease
// Neurology. 1984. Vol. 146. P. 939–44.
11. Morris J.C. The Clinical dementia rating (CDR). Current version and scoring
rules // Neurology. 1993. Vol. 43. P. 2412–413.
12. Sink K.M., Covinsky K.E., Barnes D.E. Caregiver characteristics are associated
with neuropsychiatric symptoms of dementia // J Am Geriatr Soc. 2006.
|
|
|
Vol. 54. P. 796–03.
13. Takechi H., Yamada H., Sugihara Y., Kita T. Behavio ral and psychological
symptoms, cognitive impairment and caregiver burden related to Alzheimer's
disease patients treated in an outpatient memory clinic [in Japanese] // Nippon
Ronen Igakkai Zasshi. 2006. Vol. 43. P. 207–16.
14. Wimo A., Nordberg G. Validity and reliability of assessments of time. Comparisons
of direct observations and estimates of time by the use of the
resource utilization in dementia (RUD)-instrument // Arch Gerontol Geriatr.
2007. Vol. 44(1). P. 71–1.
The role of pathogenetic treatment of Alzheimer's disease
In decrease of caregivers burden
I.V . Kolykhalov 1 , G.A. Rassadina 2
1Department of Geriatric Psychiatry, Mental Health Research
Center of Russian Academy of Medical Sciences
Kashirskoye shosse, 34, Moscow, 115522
2Psychiatric clinical hospital №15
Mockvorechje st., 7, Moscow, 115552
The efficacy and safety of four-month courses of rivastigmine
and changes in measures of caregivers burden were studied in a
non-randomized group of 25 patients with Alzheimer’ disease
(AD). All patients received p. o. rivastigmine and 22 patients
received antipsychotic therapy along with rivastigmine on admission.
Result of the study showed that the use of rivastigmine in
AD patients with behavioral and psychotic disorders at the stage
of moderately severe dementia not only improved the patients cognitive
functions, but also had positive effects in terms of decreasing
psychotic and behavioral disorders. Inclusion of rivastigmine
in the complex treatment of AD patients led to significant decreases
in the doses of psychotropic drugs, and in some patients to complete
withdrawal of all antipsychotics. It is extremely important to
emphasize that the use of rivastigmine in patients with moderately
severe AD and behavioral disorders led to significant (up to
30 %) decreases in the caregiver’ time spent on the care and
supervision of the patients, along with decreases in the level of
stress and improvements in the health of caregivers, indicating
increases in the quality of life of both patients and their families.
Key words: Alzheimer’ disease, rivastigmine, caregiver, quality
of life
Дата добавления: 2019-02-12; просмотров: 57; Мы поможем в написании вашей работы! |
Мы поможем в написании ваших работ!